Logo

OpiCalc

FavoritesSpecialtiesDrugsGuidelinesMost Used

Quick Access

Favorites
Most Used

All Specialties

OpiCalc Logo
Clinical CalculatorsDrugsGuidelines
SpecsDrugsGuides
AMD Severity ScaleAstigmatism AssistantBarrett / SRK-T SimDiabetic Retinopathy RiskGlaucoma ProgressionGlaucoma Risk (OHTS)Graves CASHFA MD to VFI ConverterIOP Correction (CCT)LogMAR <-> SnellenMRD AssessmentROP Risk (G-ROP)SPEED Score (Dry Eye)SUN Uveitis GradingVertex Distance
OpiCalc Logo

OpiCalc

Easy, fast, and private medical tools for clinicians. Always free.

No Login Required
Ready for the Bedside

Resources

About UsEditorial PolicyMedical DisclaimerPrivacy PolicyTerms of UseCookie Policy

Support

Contact Us

Clinical Notice:OpiCalc is not a substitute for professional clinical judgment. Always verify dosages and guidelines.

OpiCalc © 2026

•

All Rights Reserved

Glaucoma Progression

Guidelines & Evidence

Verified

Last Review: 2026-07-17

When to Use

Risk Assessment

Forecasting timeframe to legal blindness
Determining aggressiveness of IOP lowering
Standardizing visual field (VF) decay rates

How it Works

Mean Deviation (MD) Decay

Normal age-related MD loss is approx -0.05 to -0.1 dB/year. Progression in glaucoma is typically categorized: Slow (< -0.5 dB/y), Moderate (-0.5 to -1.0 dB/y), and Fast (> -1.0 dB/y).

Clinical Pearls

Visual Field Reliability

Always check Reliability Indices (Fixation losses, False Positives, False Negatives) before acting on a decay rate. A single poor-quality VF can erroneously accelerate the calculated progression rate.

Last Comprehensive Review: 2026-07-17

Recent Journal Updates

PLOS MedicineJul 23, 2026
Exploring parental prenatal influences on child health: A multicohort study and data visualisation tool

Clinical Context

We think this has broad domain relevance to Glaucoma Progression Analysis.

WHO NewsJul 20, 2026
Road deaths fall by 21% globally but stronger action is needed to save lives

Clinical Context

We think this has broad domain relevance to Glaucoma Progression Analysis.

Cancer MedicineJul 16, 2026
Notch3/4 Knockdown Inhibits Colon Adenocarcinoma Progression by Suppressing Tumor Cell Activity and Orchestrating VEGFA‐Dependent Tumor Immune Microenvironment

Clinical Context

We think this might be relevant to the clinical guidance for Glaucoma Progression Analysis.